Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Tuberculosis

  Free Subscription


Articles published in Am J Respir Crit Care Med

Retrieve available abstracts of 50 articles:
HTML format



Single Articles


    December 2022
  1. DOOLEY KE, Hendricks B, Gupte N, Barnes G, et al
    Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.
    Am J Respir Crit Care Med. 2022 Dec 1. doi: 10.1164/rccm.202208-1475.
    PubMed     Abstract available



  2. Erratum: Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022;206:1434.
    PubMed    


    October 2022
  3. CHECKLEY W
    Tuberculosis, Wildfires, and Case-Crossover Studies: An Epidemiological Trifecta?
    Am J Respir Crit Care Med. 2022 Oct 31. doi: 10.1164/rccm.202210-1936.
    PubMed    


    September 2022

  4. Erratum: Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2022;206:800-801.
    PubMed    


  5. LINDE LR, Readhead A, Barry PM, Balmes JR, et al
    Tuberculosis Diagnoses Following Wildfire Smoke Exposure in California.
    Am J Respir Crit Care Med. 2022 Sep 14. doi: 10.1164/rccm.202203-0457.
    PubMed     Abstract available


    June 2022
  6. MARAIS BJ, Graham SM
    The Value of Chest Radiography in Tuberculosis Preventive Treatment (TPT) Screening in Children and Adolescents.
    Am J Respir Crit Care Med. 2022 Jun 2. doi: 10.1164/rccm.202205-1023.
    PubMed    


    May 2022
  7. DOWDY DW
    Coughing is Not Required to Transmit Mycobacterium tuberculosis: Another Nail in the Coffin.
    Am J Respir Crit Care Med. 2022 May 25. doi: 10.1164/rccm.202204-0645.
    PubMed    


  8. HUANG CC, Tan Q, Becerra MC, Calderon R, et al
    The Contribution of Chest Radiography to the Clinical Management of Children Exposed to Tuberculosis.
    Am J Respir Crit Care Med. 2022 May 24. doi: 10.1164/rccm.202202-0259.
    PubMed     Abstract available


  9. DINKELE R, Gessner S, McKerry A, Leonard B, et al
    Aerosolization of Mycobacterium tuberculosis by Tidal Breathing.
    Am J Respir Crit Care Med. 2022 May 18. doi: 10.1164/rccm.202110-2378.
    PubMed     Abstract available


  10. DE JAGER V, Gupte N, Nunes S, Barnes GL, et al
    Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
    Am J Respir Crit Care Med. 2022;205:1228-1235.
    PubMed     Abstract available


  11. ESMAIL A, Oelofse S, Lombard C, Perumal R, et al
    An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Am J Respir Crit Care Med. 2022;205:1214-1227.
    PubMed     Abstract available


    April 2022
  12. SHAKU MT, Bishai WR
    Mycobacterium tuberculosis: A Pathogen That Can Hold its Breath a Long Time.
    Am J Respir Crit Care Med. 2022 Apr 20. doi: 10.1164/rccm.202203-0432.
    PubMed    


  13. BUCSAN AN, Veatch A, Singh DK, Akter S, et al
    Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022 Apr 12. doi: 10.1164/rccm.202112-2747.
    PubMed     Abstract available


  14. PITTET LF, Fritschi N, Tebruegge M, Dutta B, et al
    Bacillus Calmette-Guerin Skin Reaction Predicts Enhanced Mycobacteria-Specific T-Cell Responses in Infants: A Post Hoc Analysis of a Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2022;205:830-841.
    PubMed     Abstract available


    March 2022
  15. LANGE C, Barry Iii CE, Horsburgh CR Jr
    Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
    Am J Respir Crit Care Med. 2022 Mar 23. doi: 10.1164/rccm.202202-0393.
    PubMed    


    January 2022
  16. SCHLUGER NW
    Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents.
    Am J Respir Crit Care Med. 2022 Jan 31. doi: 10.1164/rccm.202112-2866.
    PubMed    


  17. O'DONNELL M, Mathema B
    Expanding the Tuberculosis Cascade of Care to Treat Undiagnosed and Subclinical Tuberculosis in High-Burden Settings.
    Am J Respir Crit Care Med. 2022;205:149-151.
    PubMed    


    December 2021
  18. KAUSHIK A, Ammerman NC, Tasneen R, Lachau-Durand S, et al
    Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy.
    Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541.
    PubMed     Abstract available


  19. FENNELLY KP, Martinez L, Mandalakas AM
    Tuberculosis: First in Flight.
    Am J Respir Crit Care Med. 2021 Dec 14. doi: 10.1164/rccm.202111-2513.
    PubMed    


  20. SHIMIZU T, Watanabe S, Murata A, Kasahara K, et al
    Bronchial Cast Hiding Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2021 Dec 3. doi: 10.1164/rccm.202105-1306.
    PubMed    


  21. SCHLUGER NW
    Using Isoniazid More Safely and More Effectively: The Time Is Now.
    Am J Respir Crit Care Med. 2021;204:1248-1250.
    PubMed    


    November 2021
  22. BUNYASI EW, Middelkoop K, Koch A, Hoosen Z, et al
    Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools.
    Am J Respir Crit Care Med. 2021 Nov 9. doi: 10.1164/rccm.202102-0405.
    PubMed     Abstract available


  23. ADJOBIMEY M, Behr MA, Menzies D
    Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity.
    Am J Respir Crit Care Med. 2021;204:1013-1014.
    PubMed    


    October 2021
  24. ATRE SR, Jagtap JD, Faqih MI, Dumbare YK, et al
    Tuberculosis Pathways to Care and Transmission of Multidrug-Resistance in India.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202012-4333.
    PubMed     Abstract available


  25. NOURSADEGHI M, Gupta RK
    New Insights into the Limitations of Host-Transcriptional Biomarkers of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202109-2146.
    PubMed    


    September 2021
  26. MULENGA H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, et al
    Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Sep 14. doi: 10.1164/rccm.202103-0548.
    PubMed     Abstract available


  27. DARTOIS V, Dick T
    A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?
    Am J Respir Crit Care Med. 2021;204:505-507.
    PubMed    


    August 2021
  28. DAVIS JL, Checkley W
    Characterization of Air Pollution Exposures as Risk Factors for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Aug 30. doi: 10.1164/rccm.202107-1795.
    PubMed    


  29. GAUSI K, Ignatius EH, Sun X, Kim S, et al
    A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
    Am J Respir Crit Care Med. 2021 Aug 17. doi: 10.1164/rccm.202103-0534.
    PubMed     Abstract available


  30. MITNICK CD, Furin JJ, Hewison C
    The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202106-1516.
    PubMed    


  31. VERMA R, Patil S, Zhang N, Moreira FMF, et al
    A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202103-0564.
    PubMed     Abstract available


  32. IMPERIAL MZ, Phillips PPJ, Nahid P, Savic RM, et al
    Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2021 Aug 4. doi: 10.1164/rccm.202101-0117.
    PubMed     Abstract available


  33. BLOUNT RJ, Phan H, Trinh T, Dang H, et al
    Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.
    Am J Respir Crit Care Med. 2021 Aug 3. doi: 10.1164/rccm.202101-0136.
    PubMed     Abstract available


    June 2021
  34. ROELENS M, Battista Migliori G, Rozanova L, Estill J, et al
    Evidence-based Definition for Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Jun 9. doi: 10.1164/rccm.202009-3527.
    PubMed     Abstract available


    May 2021
  35. WELLS G, Glasgow JN, Nargan K, Lumamba K, et al
    microCT Analysis of the Human Tuberculous Lung Reveals Remarkable Heterogeneity in 3D Granuloma Morphology.
    Am J Respir Crit Care Med. 2021 May 20. doi: 10.1164/rccm.202101-0032.
    PubMed     Abstract available


    April 2021

  36. Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2021;203:1045.
    PubMed    


  37. HUDDART S, Savic RM, Cattamanchi A
    Is Glycemic Control the Secret to Tuberculosis Control?
    Am J Respir Crit Care Med. 2021 Apr 7. doi: 10.1164/rccm.202103-0703.
    PubMed    


    March 2021
  38. BEHR MA, Kaufmann E, Duffin J, Edelstein PH, et al
    Latent Tuberculosis: Two Centuries of Confusion.
    Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202011-4239.
    PubMed     Abstract available


  39. LIU Q, You N, Pan H, Shen Y, et al
    Glycemic Trajectories After Tuberculosis Diagnosis and Treatment Outcomes of New Tuberculosis Patients: A Prospective Study in Eastern China.
    Am J Respir Crit Care Med. 2021 Mar 11. doi: 10.1164/rccm.202007-2634.
    PubMed     Abstract available


  40. KENDALL EA, Shrestha S, Dowdy DW
    Reply to: Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202102-0367.
    PubMed    


  41. PIERCE CW
    Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202101-0227.
    PubMed    


  42. LE ROUX SP, Upton C, Vanker N, Dooley KE, et al
    Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
    Am J Respir Crit Care Med. 2021;203:635-637.
    PubMed    


    February 2021
  43. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.
    PubMed    


    January 2021
  44. MPANDE CAM, Musvosvi M, Rozot V, Mosito B, et al
    Antigen-specific T Cell Activation Distinguishes Between Recent and Remote Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Jan 6. doi: 10.1164/rccm.202007-2686.
    PubMed     Abstract available


  45. FRANKE MF, Khan P, Hewison C, Khan U, et al
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Am J Respir Crit Care Med. 2021;203:111-119.
    PubMed     Abstract available


    December 2020
  46. HOSODA C, Ishiguro T, Shimizu Y, Kanegane H, et al
    Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.
    Am J Respir Crit Care Med. 2020;202:e144-e145.
    PubMed    


    November 2020
  47. KENDALL EA, Shrestha S, Dowdy DW
    The Epidemiological Importance of Subclinical Tuberculosis: A Critical Re-Appraisal.
    Am J Respir Crit Care Med. 2020 Nov 16. doi: 10.1164/rccm.202006-2394.
    PubMed     Abstract available


    September 2020
  48. CHANG KC, Yew WW
    ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
    Am J Respir Crit Care Med. 2020;202:777-778.
    PubMed    


  49. SOTGIU G, Battista Migliori G, Menzies D, Mase S, et al
    Reply to Chang and Yew.
    Am J Respir Crit Care Med. 2020;202:778-779.
    PubMed    


    August 2020
  50. DAWRS SN, Kautz M, Chan ED, Honda JR, et al
    Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study.
    Am J Respir Crit Care Med. 2020;202:466-469.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: